For help on how to get the results you want, see our search tips.
112 results
Keyword Remove keyword
-
List item
Summary of opinion: Velactis
cabergoline, opinion date: 05/12/2019, Negative, Last updated: 06/12/2019 -
List item
Summary of opinion: Rabitec
Rabies vaccine (live, oral) for foxes and raccoon dogs, opinion date: 23/01/2020, Positive, Last updated: 24/01/2020 -
List item
Summary of opinion: Clynav
Salmon pancreas disease vaccine (recombinant DNA plasmid), opinion date: 20/02/2020, Positive, Last updated: 21/02/2020 -
List item
Summary of opinion: Leucofeligen FeLV/RCP
feline calicivirosis, feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live), feline leukaemia vaccine (inactivated), opinion date: 25/05/2020, Positive, Last updated: 25/05/2020 -
List item
Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa
Active substance: andexanet alfa, DHPC type: Safety signal, Last updated: 17/06/2020 -
List item
Summary of opinion: Innovax-ND-IBD
Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant), opinion date: 07/10/2020, Positive, Last updated: 09/10/2020 -
List item
Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization
Active substance: andexanet alfa, DHPC type: Adverse event, Last updated: 04/11/2020 -
List item
Direct healthcare professional communication (DHPC): Metamizole: Risk of drug-induced liver injury
Active substance: metamizole, DHPC type: Periodic safety update report, Last updated: 15/12/2020 -
List item
Summary of opinion: Emdocam
meloxicam, opinion date: 17/02/2021, Positive, Last updated: 19/02/2021 -
List item
Summary of opinion: Emdocam
meloxicam, opinion date: 17/02/2021, Positive, Last updated: 19/02/2021 -
List item
Summary of opinion: Lextemy
bevacizumab, opinion date: 25/02/2021, Positive, Last updated: 26/02/2021 -
List item
Summary of opinion: Trelegy Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Elebrato Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Temybric Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Cortavance
hydrocortisone, opinion date: 18/03/2021, Positive, Last updated: 19/03/2021 -
List item
Summary of opinion: Abiraterone Krka
abiraterone acetate, opinion date: 22/04/2021, Positive, Last updated: 23/04/2021 -
List item
Summary of opinion: Koselugo
selumetinib, opinion date: 22/04/2021, Positive, Last updated: 23/04/2021 -
List item
Summary of opinion: Bonqat
pregabalin, opinion date: 12/05/2021, Positive, Last updated: 17/05/2021 -
List item
Summary of opinion: Ozawade
pitolisant, opinion date: 20/05/2021, Positive, Last updated: 21/05/2021 -
List item
Summary of opinion: Evotaz
atazanavir, cobicistat, opinion date: 21/05/2021, Positive, Last updated: 21/05/2021 -
List item
Summary of opinion: Fatrovax RHD
Rabbit haemorrhagic disease vaccine (inactivated, recombinant), opinion date: 17/06/2021, Positive, Last updated: 18/06/2021 -
List item
Summary of opinion: Tessie
tasipimidine, opinion date: 17/06/2021, Positive, Last updated: 18/06/2021 -
List item
Summary of opinion: Strangvac
Streptococcus equi vaccine (recombinant proteins), opinion date: 17/06/2021, Positive, Last updated: 18/06/2021 -
List item
Direct healthcare professional communication (DHPC): Champix (varenicline) - lots to be recalled due to presence of impurity N-nitroso-varenicline above the Pfizer acceptable daily intake limit
Active substance: varenicline, DHPC type: Quality defect, Last updated: 15/07/2021 -
List item
Direct healthcare professional communication (DHPC): Brivudine: potentially fatal toxicity of fluoropyrimidines if administered shortly before or at the same time with brivudine or used within 4 weeks after the end of treatment with brivudine
Active substance: Brivudine, DHPC type: Periodic safety update single assessment, Last updated: 12/05/2020